Split on Abortion Delays Bioethics Panel

WASHINGTON—The start of a report to Congress on fetal research, due next May, is being delayed by differences on abortion among the 12 congressional members of the Biomedical Ethics Board. Last August the board was able to appoint only the dozen “expert” members to its advisory committee. Their disagreements have prevented their filing the two slots reserved for citizens “who possess no specific expertise” in research, medicine or ethical issues. The advisory com

Written byA. J. Hostetler
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WASHINGTON—The start of a report to Congress on fetal research, due next May, is being delayed by differences on abortion among the 12 congressional members of the Biomedical Ethics Board.

Last August the board was able to appoint only the dozen “expert” members to its advisory committee. Their disagreements have prevented their filing the two slots reserved for citizens “who possess no specific expertise” in research, medicine or ethical issues. The advisory committee, whose members serve for four years, will report on ethical issues involving health care delivery, biomedical and behavioral research, protection of human subjects and developments in genetic engineering “which have implications for human genetic engineering.” A second report, on that subject, is due no later than 18 months after all 14 members have been appointed.

The legislation setting up the board requires that committee candidates receive at least eight board members’ votes for appointment to the committee. ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies